close

LATEST POSTS from Anne-Lise Berthier

Trend Chart on Innovative Biotherapies – January 15th, 2020

Trend Chart on Innovative Biotherapies - January 15th, 2020 FEATURE STORY ● The National Gene Vector Biorepository. Eleven years of providing resources to the gene therapy community GENE THERAPY ● Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays DISRUPTIVE TECHNOLOGIES ● A small molecule-controlled Cas9 repressible system…..

Trend Chart On Innovative BioIndustries – November 7th, 2019

FEATURE STORY ● The Alliance for Regenerative Medicine outlines recommendations to increase the number of European-based ATMP clinical trials GENE THERAPY ● Long-term correction of copper metabolism in WD mice with AAV8 vector delivering truncated ATP7b ● Enhancing the therapeutic potentiel of sulfamidase for the treatment of MPSIIIA DISRUPTIVE TECHNOLOGIES…..

New R&D agreement to expand Ziopharm’s TCR-T Program

New R&D agreement to expand Ziopharm's TCR-T Program Ziopharm Oncology, an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy, has concluded a new R&D agreement with MD Anderson Cancer Center. This agreement is related…..

Transforming DNA repair errors into assets

Transforming DNA repair errors into assets A new bioinformatics tool, MHcut, developed by researchers in Kyoto, Japan, and Montreal, Canada, reveals that a natural repair system for DNA damage, microhomology-mediated end joining, is probably far more common in humans than originally assumed. Using MHcut and commercial genome-editing technology, the researchers created…..